Mediastinal large B-cell lymphoma (MLBL) represents only 2% of mature B-cell non-Hodgkin lymphoma (B-NHL) Alternate treatment strategies should be investigated in the future taking into account both adult MLBL approaches and more recent biological findings in adult MLBL.
Introduction
Mediastinal large B-cell lymphoma (MLBL) is a rare malignancy thought to arise from mature thymic B-cells. Although previously considered by the World Health Organization (WHO) to be a subtype of diffuse large B-cell lymphoma (DLBCL) 1 , primary mediastinal large B-cell lymphoma (PMBL) is now classified as a distinct mature B-cell neoplasm. 2 According to the Murphy staging system for childhood non-Hodgkin's lymphoma (NHL), MLBL, by virtue of its primary location in the mediastinum, must be at least stage III disease, even when tumor is localized above the diaphragm. 3 The Children's Cancer Group (CCG) and Berlin-FrankfurtMunster (BFM) Group each reported results in children with mediastinal disease enrolled in series of completed multi-center mature B-NHL trials, and demonstrated 5-year event-free survival (EFS) of 75% ± 10% and 75% ± 8%, respectively. 4, 5 In contrast, a considerably higher 5-yr EFS of 85% ± 2% was reported for BFM patients with stage III non-primary-mediastinal Bcell NHL who received the same therapy as those with primary mediastinal disease, suggesting that MLBL may be an inherently different disease that requires alternative therapy than other identically grouped pediatric mature B-cell NHLs.
With the advent of gene expression profiling, it has become apparent that adult PMBL differs biologically from other mature B-cell NHLs, including DLBCL subtypes [1] [2] [3] 6 and Burkitt's lymphoma (BL), 7 and may in fact be a separate disease entity altogether. DNA microarrays have demonstrated similarities between PMBL and Hodgkin lymphoma (HL), suggesting that PMBL falls somewhere along the biological spectrum between DLBCL and HL. 6, 8 Recent studies have suggested that molecular hallmarks of PMBL include overexpression of genes in both NFĸB and JAK/STAT pathways ( Figure 1 ). 9 For personal use only. on . by guest www.bloodjournal.org From 
Materials and Methods

General
The 
Treatment and randomization
Patients with Stage III MLBL and Stage III non-MLBL DLBCL were initially assigned to the group B treatment arm as we have previously described. 10 Patients received a pre-phase 
Statistical Methods
The primary endpoint was EFS, defined as the time from randomization to disease progression, relapse, second malignancy, or death from any cause. Overall survival (OS) was a secondary endpoint. OS was defined as the time from randomization to death from any cause. For determination of EFS and OS, patients who did not experience an event were censored at the date of last follow-up contact. Probability of EFS and OS were determined using the Kaplan- ≥ 2X ULN) were performed using a log rank test.
Results
Demographics
Forty-two patients with MLBL primary arising out of the mediastinum were enrolled, constituting approximately 5% of the total number of patients registered in Group B therapy (n=762). Demographic information for the MLBL subset is summarized in Table 1 . All patients were adolescents (median age 15.7 yrs) and the majority of patients were female (F:M, 3:2).
Patients were enrolled from all 3 cooperative groups, with the majority receiving treatment at COG sites.
Pathology
All MLBL cases showed compartmentalizing sclerosis surrounding medium to large sized tumor cells ( Figure 2A ). The tumor cells had moderate amounts of clear cytoplasm with round to oval vesicular nuclei. Nucleoli were not prominent. Immunophenotypic analysis showed expression of the B-cell markers CD20 and CD79a in all cases. The tumor cells were negative for CD3, CD45RO, TdT and p80. All cases showed CD30 staining that was variable in intensity but usually weak and patchy in distribution in a predominantly cytoplasmic distribution. In the small subset of eleven cases stained for germinal center markers, 15 it was noted that 2/11 cases expressed CD10 and BCL-6, 7/11 expressed BCL6 without CD10 ( Figure 2B ) and 2 cases showed only MUM-1 without CD10 or BCL-6 expression. Interestingly, all cases (11/11), irrespective of germinal center marker expression, showed IRF4/MUM-1 staining ( Figure 2C ). cases had features that were indeterminate between DLBCL (NOS) and PMBL including large cell morphology with no discernable fibrosis and variable, weak CD30 expression.
Response to Treatment
The treatment course and response for each of the 42 MLBL patients is summarized in Figure 3 .
There were no toxic deaths on study. Of the 42 MLBL patients who were received COP therapy, 36 (84%) had at least a 20% response. No patient had evidence of disease progression at the
evaluation (after COPADM1). Six patients transferred to Group C after COP therapy.
Among the remaining 36 patients, 32 were randomized 36 according to the Group B therapy randomization as previously described. 12 For patients were not randomized and treated on the B1
arm by physician choice. Eleven patients (7 randomized, 4 not randomized) were treated on the standard B1 arm, 8 were randomized and treated on arm B2, 10 on arm B3, and 7 on arm B4.
Twenty-nine subjects on the B arms achieved a CR during the course of group B therapy, though one of these patients relapsed before the 3rd evaluation and was therefore no longer included among the CRs at CYM2 (Figure 3 Five patients with evidence of residual disease (4 histologic disease, 1 PET-positive) switched to Group C therapy after the third evaluation (after CYM1) with one additional patient was transferred to Group C despite having achieved CR.by physician choice (Figure 3 ). Excluding the 1 Group C subject already in CR at time of transfer, 8 of 11 patients in Group C attained CR.
In group C, 3 patients failed to achieve a CR after CYVE2 (induction failure); all 3 subsequently died from progressive disease. Lastly, among the different histologies, within the group of 18 patients with PMBL histology, 13 remain in CCR; within the group of 5 with DLBCL histology,
EFS and OS
In the 42 MLBL patients, the probability of 5-yr EFS and OS were 66% (95% CI: 50-78%) and The probability of 5-yr EFS in the MLBL group (n=42) was compared to the probability of 5-yr EFS in patients with Stage III non-MLBL DLBCL (n=69). 12 The MLBL group had a significantly lower 5-yr EFS compared to non-MLBL DLBCL stage III subgroup, 66% (95% CI:
49-78%) vs 85% (95% CI: 71-92%), respectively, p<.001 ( Figure 5 ).
Risk Factors Associated with EFS
In order to determine the effect of various risk factors on the probability of 5-year EFS, log-rank testing with stratification for gender, age, COP response, LDH level, and size of mass (>10cm versus ≤ 10cm) was performed. There was no difference in probability of 5-year EFS among each However, the numbers in each group were extremely low to have a high level of confidence.
Large numbers would be required to determine the independent effect of each of these variables.
Discussion
MLBL is a rare subtype of B-cell NHL, accounting for approximately 2% of childhood and adolescent lymphomas. 17 Despite its rarity, the treatment of adolescent MLBL is a topic of considerable interest, as childhood and adolescent patients with MLBL tend to have worse outcomes than do children and adolescent patients with other stage III mature B-cell NHLs. 5 The BFM group was the first to report a decreased EFS in pediatric MLBL patients (75% vs. 19-21 Additionally, in a small series of adult patients with newly diagnosed PMBL, VACOP-B followed by autologous stem cell transplant led to a disease-free survival rate of 93% after 35 months median follow-up. 22 Rituximab, the CD20 monoclonal antibody known to inhibit the anti-apoptotic NF-kB pathway, has also been extensively studied in adults with DLBCL. Rituximab is of interest in the treatment of B-cell NHL as upregulation of subsets of NF-kB signaling genes in PMBL and activated Bcell-like (ABC) DLBCL has been demonstrated by gene expression profiling. 6, 23 The addition of rituximab to CHOP therapy (CHOP-R) has been shown to provide a benefit over CHOP alone in adults with DLBCL. [24] [25] [26] Similarly, the addition of rituximab to DA-EPOCH (dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin) in adults has been shown to benefit adults with DLBCL whose tumors overexpress Bcl-2. 27 Although this latter study did not include patients with PMBL, a separate study of 32 adult patients with PMBL (Bcl-2 status not reported) treated with DA-EPOCH and rituximab demonstrated that the regimen was highly 28 Among adult patients with PMBL, who also received an intensified CHOP regimen and rituximab, this strategy has also shown very encouraging results. 29, 30 The pathology review, although limited by materials available, showed the need for careful clinical, morphologic and immunophenotypic examination to ensure that the mediastinal lymphoma is appropriately diagnosed. Although most cases of PMBL were relatively easily diagnosed, awareness of the "grey zone" lymphomas or those lymphomas with features that were indeterminant between classical HL and PMBL is necessary as these tend to be seen, albeit in low incidence, in adolescents and young adults, as was recently demonstrated in a recent retrospective study. 18 We noted 5 cases that would need additional immunophenotypic work-up to distinguish between PMBL and "grey zone" lymphoma, although there were not sufficient materials available in this retrospective study to allow for this immunophenotyping to be performed, and this incidence of cases is similar to that seen in a previous study of mature B-cell lymphoma in children and adolescents. 18 It is also important to recognize that all DLBCL that occur in the chest or mediastinum are not PMBL or "grey zone" lymphomas, but there are some cases of DLBCL, NOS that may initially present in this anatomic site although they often have evidence of disease in other sites. Both DLBCL, NOS and "grey zone" lymphomas may require different approaches to therapy than PMBL and have different prognostic implications and clinical behavior. Because of the diversity of lymphoid neoplasms that may present in the mediastinum, it is essential that a sufficient amount and quality of diagnostic materials be collected to allow for appropriate diagnostically important ancillary studies. In addition, some cases may require review by an experienced hematopathologist with appropriate immunophenotyping to meet the defined diagnostic criteria set forth in the 2008 WHO Classification for accurate diagnosis and differentiation between PMBL, DLBCL (NOS) and "grey zone" lymphoma. 18, 31 Aside from rituximab, other inhibitors of the NF-kB pathway could be of benefit to patients with PMBL. NF-kB blocking agents such as proteasome inhibitors and small molecule inhibitors of the IKK protein may work synergistically with chemotherapy and rituximab and warrant further study. By blocking the pathway at various points in the NF-kB signal transduction pathway, it may be possible to overcome any compensatory up-regulation that may occur. Preliminary activity of proteasome inhibitors and small molecule IKK inhibitors has already been demonstrated in vitro in a PMBL cell line, with increases in apoptosis reported following incubation with a proteasome inhibitor, a small molecule IKK inhibitor or the combination of both. Additionally, these increases in apoptosis were shown to be associated with inhibition of multiple apoptosis-associated proteins, including members of the NF-kB family of transcription factors. 32 The NF-kB signaling pathway is not the only pathway that is overexpressed in PMBL.
Constitutive activation of the JAK-STAT signaling pathway due to recurrent gene mutations affecting the STAT6 DNA binding domain has been demonstrated in PMBL tumor samples, but not in DLBCL tumor samples. 9, 33 Targeted agents that block the JAK-STAT pathway may therefore also prove useful in the treatment of PMBL (Figure 1 ). 9, 33 Recent studies have demonstrated a consistent 9p24.1 amplification in adult PMBL and enhanced expression of PD-1 ligand. 34 Lastly, reduced expression of MHC class II genes is an additional defining feature of adult PMBL with a strong correlation with expression of the master transcriptional regulator of
For personal use only. on October 24, 2017. by guest www.bloodjournal.org From class II expression (CITA). [35] [36] [37] Immunological approaches attempting to block PD-1 and/or increasing T-cell effector cells infiltration into the microenvironment may be additional alternative treatment strategies to consider in the future.
It is important to consider alternative chemotherapy regimens and the addition of targeted agents early in the treatment of all patients with adolescent MLBL, as patients who do not achieve a complete response with first-line therapy are difficult to retrieve with subsequent therapies. This is evidenced by the finding that all 3 of the patients switched to Group C therapy who were not in CR after the second CYVE2 intensification cycle went on to die of their disease. Although more intensive and targeted therapies may be important for all adolescent MLBL patients, they are most urgently needed for the treatment of patients without an early response to chemotherapy. Despite the fact that COP non-responders were switched to more-intensive Group C therapy, two of these patients still failed to achieve a complete response and subsequently died from disease progression. Furthermore, the single patient who did not respond to COP but remained on Group B therapy also went on to relapse after the completion of treatment and subsequently died. 
